3142 related articles for article (PubMed ID: 6852975)
1. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells.
Livingston PO; Takeyama H; Pollack MS; Houghton AN; Albino A; Pinsky CM; Oettgen HF; Old LJ
Int J Cancer; 1983 May; 31(5):567-75. PubMed ID: 6852975
[TBL] [Abstract][Full Text] [Related]
2. [Vaccine therapy of malignant melanoma. II. Serological evaluation of the immune responses to the injection using allogeneic melanoma cell vaccine].
Takeyama H; Watanabe T; Livingston PO
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1624-33. PubMed ID: 6870307
[TBL] [Abstract][Full Text] [Related]
3. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells.
Livingston PO; Albino AP; Chung TJ; Real FX; Houghton AN; Oettgen HF; Old LJ
Cancer; 1985 Feb; 55(4):713-20. PubMed ID: 2981601
[TBL] [Abstract][Full Text] [Related]
4. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines.
Livingston PO; Kaelin K; Pinsky CM; Oettgen HF; Old LJ
Cancer; 1985 Nov; 56(9):2194-200. PubMed ID: 4052966
[TBL] [Abstract][Full Text] [Related]
5. Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.
Houghton AN; Taormina MC; Ikeda H; Watanabe T; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1980 Jul; 77(7):4260-4. PubMed ID: 6933476
[TBL] [Abstract][Full Text] [Related]
6. [Serological analysis of melanoma patients receiving autologous melanoma cell vaccines].
Watanabe T
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):261-72. PubMed ID: 6881976
[TBL] [Abstract][Full Text] [Related]
7. Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells.
Livingston PO; Watanabe T; Shiku H; Houghton AN; Albino A; Takahashi T; Resnick LA; Michitsch R; Pinsky CM; Oettgen HF; Old LJ
Int J Cancer; 1982 Oct; 30(4):413-22. PubMed ID: 7141736
[TBL] [Abstract][Full Text] [Related]
8. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine.
Bystryn JC; Henn M; Li J; Shroba S
Cancer Res; 1992 Nov; 52(21):5948-53. PubMed ID: 1382848
[TBL] [Abstract][Full Text] [Related]
9. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
Anichini A; Maccalli C; Mortarini R; Salvi S; Mazzocchi A; Squarcina P; Herlyn M; Parmiani G
J Exp Med; 1993 Apr; 177(4):989-98. PubMed ID: 8459226
[TBL] [Abstract][Full Text] [Related]
10. Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody.
Real FX; Mattes MJ; Houghton AN; Oettgen HF; Lloyd KO; Old LJ
J Exp Med; 1984 Oct; 160(4):1219-33. PubMed ID: 6237165
[TBL] [Abstract][Full Text] [Related]
11. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.
de Vries JE; Spits H
J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458
[TBL] [Abstract][Full Text] [Related]
12. Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.
Shiku H; Takahashi T; Oettgen HF
J Exp Med; 1976 Oct; 144(4):873-81. PubMed ID: 978138
[TBL] [Abstract][Full Text] [Related]
13. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
Hom SS; Topalian SL; Simonis T; Mancini M; Rosenberg SA
J Immunother (1991); 1991 Jun; 10(3):153-64. PubMed ID: 1868040
[TBL] [Abstract][Full Text] [Related]
14. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.
Darrow TL; Slingluff CL; Seigler HF
J Immunol; 1989 May; 142(9):3329-35. PubMed ID: 2785141
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients.
Walton SM; Gerlinger M; de la Rosa O; Nuber N; Knights A; Gati A; Laumer M; Strauss L; Exner C; Schäfer N; Urosevic M; Dummer R; Tiercy JM; Mackensen A; Jaeger E; Lévy F; Knuth A; Jäger D; Zippelius A
J Immunol; 2006 Dec; 177(11):8212-8. PubMed ID: 17114498
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of a polyvalent human melanoma antigen vaccine.
Bystryn JC; Jacobsen S; Harris M; Roses D; Speyer J; Levin M
J Biol Response Mod; 1986 Jun; 5(3):211-24. PubMed ID: 3723138
[TBL] [Abstract][Full Text] [Related]
17. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens.
Jäeger E; Bernhard H; Romero P; Ringhoffer M; Arand M; Karbach J; Ilsemann C; Hagedorn M; Knuth A
Int J Cancer; 1996 Apr; 66(2):162-9. PubMed ID: 8603805
[TBL] [Abstract][Full Text] [Related]
18. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
[TBL] [Abstract][Full Text] [Related]
19. A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine.
Hayashi Y; Hoon DS; Foshag LJ; Park MS; Terasaki PI; Morton DL
Cancer; 1993 Aug; 72(3):750-9. PubMed ID: 8334627
[TBL] [Abstract][Full Text] [Related]
20. Isolation and immunochemical characterization of antibodies from the sera of cancer patients which are reactive against human melanoma cell membranes by affinity chromatography.
Gupta RK; Silver HK; Reisfeld RA; Morton DL
Cancer Res; 1979 May; 39(5):1683-95. PubMed ID: 427806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
